Wintermute Biomedical
- Home
- Companies
- Wintermute Biomedical
- Services
- Flagship Developments and Research ...
Flagship Developments and Research Services
Wintermute launched the Doxall™ Sanitiser range in 2021 and has multiple other therapeutic formulations in its development pipeline. These including a Covid 19 preventative and treatment inhalant and a topical shingles therapeutic. Wintermute formulations demonstrate exceptional potential for the treatment of infections. Some key advantages of include.
Most popular related searches
in vivo tests
in vivo testing
in vivo test
COVID 19
in vitro test
COVID-19 treatment
in vivo activity
infection treatment
infection protection
therapeutic development
- High-efficacy : High levels of potency in eradication infectious organisms.
- Excellent safety : High levels of safety captured during in-vitro and in-vivo testing.
- Broad spectrum : Activity against gram-positive and gram-negative bacteria, fungi and viruses.
- Combats resistance : Zero evidence of resistance development during standardized testing (undecylenic acid formulation)
- Long lasting : Ongoing protection against infections.
- Environmentally Friendly : No harmful chemicals, water-based, sustainable naturally occurring active ingredients.